Bio-Techne Earnings Call Balances Weak Sales, Strong Margins

Bio-Techne ((TECH)) has held its Q3 earnings call. Read on for the main highlights of the call.

Bio‑Techne’s latest earnings call struck a cautiously optimistic tone as management balanced near‑term revenue softness with clear pockets of strength. Executives highlighted robust momentum in spatial biology, GMP proteins and large pharma demand, alongside improving margins and cash generation. Yet they also acknowledged a 2% organic revenue decline and sustained pressure from emerging biotech customers.

Spatial Biology and COMET Platform Scale Up

Spatial biology remained a standout, delivering mid‑teens growth in the quarter and underscoring its role as a key growth engine. The COMET Multiomic Spatial Platform grew more than 65% and exited the quarter with a record backlog, including the first COMET installation in China that supports ongoing international expansion.

GMP Protein Portfolio Growth Despite Timing Noise

The company’s GMP protein portfolio posted nearly 50% year‑over‑year growth when excluding two fast‑track cell therapy customers that caused timing distortions. Management framed this performance as evidence of strong structural demand from advancing cell therapy programs, even as certain large projects temporarily slowed ordering patterns.

Proteomic Analysis and Regulatory Win in Europe

Proteomic Analysis instruments delivered mid‑single‑digit growth, supported by favorable placements and increasing utilization across customer labs. The Ella platform remained a bright spot with a 50% three‑year CAGR in neurology assays and secured CE‑IVD marking, opening the door to broader clinical adoption in Europe.

Large Pharma and China Provide End‑Market Resilience

Large pharmaceutical customers delivered their sixth straight quarter of double‑digit growth, helping offset weakness in earlier‑stage customers. China recorded its fourth consecutive quarter of positive organic growth in the low single digits, with rising demand from biopharma and CRO/CDMO clients focused on ADCs, cell therapy and autoimmune indications.

Sequential Margin Expansion Signals Operational Discipline

Profitability improved meaningfully on a sequential basis as adjusted operating margin reached 34.2%, up 310 basis points from fiscal Q2. Adjusted gross margin increased 190 basis points to 70.4%, reflecting better mix versus the prior quarter and continued cost discipline even against a softer revenue backdrop.

Strong Cash Generation and Conservative Balance Sheet

Bio‑Techne generated $86.7 million of operating cash flow in Q3 while limiting net capital expenditures to $9.1 million. The company ended the quarter with $209.8 million in cash, $200 million of bank debt and total leverage below 1x EBITDA, preserving flexibility for investment and potential strategic actions.

EPS Performance and GAAP Profitability Improvement

Adjusted EPS came in at $0.53, down $0.03 from the prior year as mix and volume headwinds weighed on the top line. GAAP EPS, however, improved to $0.32 from $0.14 a year ago, signaling progress on GAAP profitability even as the company manages through a choppy demand environment.

Portfolio Simplification and AI‑Driven Strategy

Management announced a strategic brand realignment that consolidates 10 legacy brands into three: R&D Systems, Bio‑Techne Spatial Biology and Bio‑Techne Diagnostics. The company is also investing in AI to design novel proteins using decades of proprietary data and aims to become a key data provider for AI‑driven drug discovery.

Revenue Decline and Macro Headwinds

Total Q3 revenue was $311.4 million, down 2% on both a reported and organic basis despite a 2% foreign exchange tailwind. Management pointed to prior divestiture effects and timing issues as notable headwinds, compounding broader softness in certain research‑focused and early‑stage customer segments.

Persistent Weakness in Emerging Biotech Spending

Emerging biotech revenue declined high single digits as these customers continued to delay spending despite improving funding statistics. Executives reminded investors that there is typically a two to three quarter lag between funding rounds and actual lab purchasing, which has been particularly visible in research‑use‑only products.

Timing Headwinds From Cell Therapy and OEM Orders

Order timing from two FDA fast track cell therapy customers and a large OEM commercial supply order created an estimated 400‑basis‑point headwind in Q3. Management expects the cell therapy component of this drag to moderate to roughly 150 basis points in Q4 before fully rolling off by fiscal 2027 as orders normalize.

Core Reagents and Assays Impacted by Early‑Stage Softness

The core reagents and assays portfolio, spanning around 6,000 proteins and 400,000 antibody types, declined mid‑single digits in the quarter. Adjusting for the OEM timing effect, the decline was limited to low single digits, which management tied primarily to weakness in early‑stage discovery funding.

Diagnostics Segment Volatility and Reporting Pressure

The Diagnostics business, now under the Bio‑Techne Diagnostics brand, declined low single digits and dragged the broader Diagnostics & Spatial Biology segment down 4% year over year. The prior divestiture of Exosome Diagnostics reduced reported growth by about 8%, illustrating how large customer orders can make results lumpy.

Year‑Over‑Year Margin Pressure From Mix and Volume

While margins expanded sequentially, adjusted operating margin was down 70 basis points year over year at 34.2% and adjusted gross margin slipped to 70.4% from 71.6%. Management cited unfavorable product mix and volume deleverage as the main drivers of this year‑over‑year compression amid uneven demand.

Surprise Shortfall in Early‑Stage Biotech Funding

Executives highlighted an unexpected decline in early‑stage biotech funding even as late‑stage funding climbed sharply. This skew has disproportionately hurt research‑use‑only core reagents tied to early discovery, contributing to weaker‑than‑expected revenue in that portion of the business despite better macro funding headlines.

Guidance and Outlook

For Q4, management expects organic revenue to be approximately flat, with low single‑digit underlying growth once the GMP and cell‑therapy timing headwind is excluded. Looking further out, they plan about 100 basis points of year‑over‑year margin expansion in Q4 and indicated they would be disappointed if fiscal 2027 did not at least deliver mid‑single‑digit growth as funding translates into higher customer spending.

Bio‑Techne’s call painted a picture of a company navigating near‑term turbulence while strengthening its growth platforms and profitability. Investors will be watching whether emerging biotech spending and core reagents recover on the expected lag, and whether spatial biology, GMP proteins and large pharma demand can drive the anticipated inflection heading into fiscal 2027.